Theravance Biopharma Inc (0TB) - Net Assets

Latest as of September 2025: €232.68 Million EUR ≈ $272.03 Million USD

Based on the latest financial reports, Theravance Biopharma Inc (0TB) has net assets worth €232.68 Million EUR (≈ $272.03 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€415.46 Million ≈ $485.72 Million USD) and total liabilities (€182.78 Million ≈ $213.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 0TB strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€232.68 Million
% of Total Assets	56.01%
Annual Growth Rate	-4.89%
5-Year Change	N/A
10-Year Change	-27.78%
Growth Volatility	57.69

Theravance Biopharma Inc - Net Assets Trend (2014–2024)

This chart illustrates how Theravance Biopharma Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Theravance Biopharma Inc market capitalisation.

Annual Net Assets for Theravance Biopharma Inc (2014–2024)

The table below shows the annual net assets of Theravance Biopharma Inc from 2014 to 2024. Also explore 0TB net asset momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2024-12-31	€175.54 Million ≈ $205.23 Million	-17.58%
2023-12-31	€213.00 Million ≈ $249.01 Million	-51.79%
2022-12-31	€441.80 Million ≈ $516.51 Million	+230.49%
2021-12-31	€-338.57 Million ≈ $-395.83 Million	-11.46%
2020-12-31	€-303.75 Million ≈ $-355.12 Million	-35.70%
2019-12-31	€-223.84 Million ≈ $-261.69 Million	-333.89%
2018-12-31	€-51.59 Million ≈ $-60.31 Million	-144.79%
2017-12-31	€115.18 Million ≈ $134.66 Million	-67.11%
2016-12-31	€350.23 Million ≈ $409.46 Million	+44.09%
2015-12-31	€243.06 Million ≈ $284.17 Million	-16.12%
2014-12-31	€289.79 Million ≈ $338.79 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Theravance Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 82618500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	€1.14 Billion	650.01%
Total Equity	€175.54 Million	100.00%

Theravance Biopharma Inc Competitors by Market Cap

The table below lists competitors of Theravance Biopharma Inc ranked by their market capitalization.

Company	Market Cap
HIT Welding Industry Co. Ltd. SHE:301137	$828.75 Million
Nesco Limited NSE:NESCO	$828.82 Million
Tian Jin Motor Dies Co Ltd SHE:002510	$828.89 Million
Cablevision Holding SA BA:CVH	$829.01 Million
Heritage Commerce Corp NASDAQ:HTBK	$828.43 Million
Adlai Nortye Ltd. American Depositary Shares NASDAQ:ANL	$828.16 Million
Anhui Sierte Fertilizer Industry Ltd Co SHE:002538	$828.10 Million
Abacus Life Inc. NASDAQ:ABL	$827.97 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Theravance Biopharma Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 212,995,000 to 175,545,000, a change of -37,450,000 (-17.6%).
Net loss of 56,418,000 reduced equity.
Share repurchases of 3,104,000 reduced equity.
New share issuances of 99,000 increased equity.
Other factors increased equity by 21,973,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-56.42 Million	-32.14%
Share Repurchases	€3.10 Million	-1.77%
Share Issuances	€99.00K	+0.06%
Other Changes	€21.97 Million	+12.52%
Total Change	€-	-17.58%

Book Value vs Market Value Analysis

This analysis compares Theravance Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.11x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 6.89x to 4.11x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	€2.12	€14.60	x
2018-12-31	€-0.93	€14.60	x
2019-12-31	€-3.93	€14.60	x
2020-12-31	€-4.72	€14.60	x
2021-12-31	€-4.59	€14.60	x
2022-12-31	€6.77	€14.60	x
2023-12-31	€4.43	€14.60	x
2024-12-31	€3.55	€14.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Theravance Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -32.14%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -87.63%
• Asset Turnover: 0.18x
• Equity Multiplier: 2.02x
Recent ROE (-32.14%) is below the historical average (-29.06%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-81.80%	-2028.05%	0.03x	1.17x	€-266.02 Million
2015	-74.97%	-432.56%	0.14x	1.23x	€-206.53 Million
2016	-54.44%	-391.94%	0.08x	1.83x	€-225.69 Million
2017	-247.79%	-1854.97%	0.03x	3.83x	€-296.92 Million
2018	0.00%	-357.01%	0.11x	0.00x	€-210.37 Million
2019	0.00%	-322.08%	0.18x	0.00x	€-214.07 Million
2020	0.00%	-386.90%	0.15x	0.00x	€-247.64 Million
2021	0.00%	-360.55%	0.15x	0.00x	€-165.57 Million
2022	197.40%	1698.54%	0.08x	1.37x	€827.95 Million
2023	-25.91%	-96.11%	0.15x	1.79x	€-76.49 Million
2024	-32.14%	-87.63%	0.18x	2.02x	€-73.97 Million

Industry Comparison

This section compares Theravance Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $167,658,839
Average return on equity (ROE) among peers: -39.80%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Theravance Biopharma Inc (0TB)	€232.68 Million	-81.80%	0.79x	$828.57 Million
TME PHARM.CONF.IPO EO 1- (0N6A)	$-1.27 Million	0.00%	0.00x	$10.44 Million
PROQR THERAPEUTICS EO-04 (0PQ)	$113.23 Million	-53.64%	0.85x	$142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP)	$19.57 Million	-78.67%	0.35x	$141.34 Million
I-MAB SPONS.ADS/1 -0001 (0VY)	$201.16 Million	-11.05%	0.06x	$186.58 Million
PreveCeutical Medical Inc (18H)	$-5.78 Million	0.00%	0.00x	$3.34 Million
Argen-X (1AE)	$344.93 Million	-8.14%	0.08x	$41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5)	$39.63 Million	-145.12%	5.94x	$854.77 Million
BIOCURE TECHNOLOGY INC. (1WH)	$1.34 Million	-19.58%	0.49x	$960.84K
ZAI LAB LTD0000006 (1ZLB)	$796.12 Million	-42.03%	0.30x	$1.82 Billion

About Theravance Biopharma Inc

F:0TB Germany Biotechnology

Market Cap

$864.92 Million

€739.82 Million EUR

Market Cap Rank

#9748 Global

#1199 in Germany

Share Price

€14.60

Change (1 day)

+0.00%

52-Week Range

€11.60 - €17.50

All Time High

€38.30